MONMOUTH JUNCTION, N.J.,
Nov. 26, 2014 /PRNewswire/
-- CytoSorbents Corporation (OTCQB: CTSO), a critical care
immunotherapy company commercializing its CytoSorb® cytokine
adsorber to treat deadly inflammation in critically-ill patients in
multiple countries worldwide, announced its activities surrounding
the 2014 DIVI Critical Care Congress from December 2-5, 2014 in Hamburg, Germany.
- CytoSorbents will host its Second CytoSorb® Users Meeting on
December 2, 2014, with the
participation of 21 speakers from throughout Germany, Austria, and Switzerland, who will share their CytoSorb®
clinical treatment experiences with the group. Following the
highly successful inaugural CytoSorb® Users Meeting at last year's
DIVI 2013, this year's meeting will feature renowned experts in
Sepsis and SIRS (the systemic inflammatory response syndrome)
including the President, Prof. Dr. med. Herwig Gerlach and the Managing Director, Prof.
Dr. med. Frank M. Brunkhorst, of the German Sepsis
Society. The day-long meeting will be focused on how best to
treat patients with CytoSorb® in three distinct sessions:
Sepsis, Cardiac Surgery, and Other Applications, with both lectures
and posters from the growing number of CytoSorb® treatment
pioneers
- CytoSorbents will also host a research symposium during the
2014 DIVI Congress at the Congress Center Hamburg on December 4, 2014 from 8:30-10AM CET focused on:
- Using blood purification to treat severe sepsis: Prof.
Dr. med. Herwig Gerlach -
Berlin, Germany
- Clinical experiences with CytoSorb® in patients with severe
sepsis: Prof. Dr. med. Michael
Quintel - Goettingen, German
- An update on the International CytoSorb® Registry: Prof.
Dr. med. Frank Brunkhorst – Jena,
Germany
- CytoSorbents will also be out in force, exhibiting at its booth
during the entire conference, increasing the exposure of CytoSorb
and strengthening relationships in the medical community
CytoSorbents plans to give an update of the conference following
the meeting. Please also look for updates on both Facebook
and Twitter.
DIVI, or the German Interdisciplinary Coalition for Intensive
Care and Emergency Medicine, is one of the premier German medical
societies dedicated to improving outcomes in patients in the
intensive care unit and emergency room. Its members primarily
consist of critical care and emergency medicine physicians, nurses,
and other healthcare providers of all levels of experience
throughout the region. Last year's DIVI 2013 Congress
attracted approximately 3,000 attendees from the region.
About DIVI
The DIVI (Deutsche Interdisziplinaere Vereinigung fur Intensiv-
und Notfallmedizin) Society was founded in 1977 to foster the
cooperation and exchange of knowledge and information between
physicians, nurses and other healthcare professionals who
specialize in intensive care and emergency medicine. The goal of
this premier organization is to foster a collaborative environment
where advances in medicine and patient care can be shared, to
benefit the welfare of patients.
http://www.divi2014.de/startseite
About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused
immunotherapy company using blood purification to control severe
inflammation -- with the goal of preventing or treating multiple
organ failure in life-threatening illnesses. Organ failure is the
cause of nearly half of all deaths in the intensive care unit, with
little to improve clinical outcome. CytoSorb®, the Company's
flagship product, is approved in the European Union as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the
"cytokine storm" that could otherwise cause massive inflammation,
organ failure and death in common critical illnesses such as
sepsis, burn injury, trauma, lung injury, and pancreatitis. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorb® is also being used
during and after cardiac surgery to remove inflammatory mediators,
such as cytokines and free hemoglobin, which can lead to
post-operative complications, including multiple organ
failure.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. CytoSorbents has numerous products
under development based upon this unique blood purification
technology, protected by 32 issued US patents and multiple
applications pending, including HemoDefend™, ContrastSorb,
DrugSorb, and others. Additional information is available for
download on the Company's website:
http://www.cytosorbents.com/.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 31, 2014, as updated
by the risks reported in our Quarterly Reports on Form 10-Q, and in
the press releases and other communications to shareholders issued
by us from time to time which attempt to advise interested parties
of the risks and factors which may affect our business. We caution
you not to place undue reliance upon any such forward-looking
statements. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise, other than as required
under the Federal securities laws.
Please Click to Follow Us on Facebook and
Twitter
Logo -
http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-to-host-second-cytosorb-users-meeting-and-symposium-at-the-divi-critical-care-congress-300001576.html
SOURCE CytoSorbents Corporation